Digital Therapeutics in Urology: An Innovative Approach to Patient Care and Management

被引:3
|
作者
Rodler, Severin [1 ]
Kowalewski, Karl-Friedrich [2 ]
Scheibert, Henriette [1 ]
Bensel, Moritz [1 ]
Stadelmeier, Leo Federico [1 ]
Styn, Amelie [1 ]
Belenchon, Ines Rivero [3 ]
Taratkin, Mark [4 ]
Puliatti, Stefano [5 ]
Rivas, Juan Gomez [6 ]
Veccia, Alessandro [7 ]
Piazza, Pietro [8 ]
Checcucci, Enrico [9 ]
Michel, Maurice S. [2 ]
Stief, Christian G. [1 ]
Cacciamani, Giovanni [10 ]
机构
[1] LMU Univ Hosp, Dept Urol, Munich, Germany
[2] Heidelberg Univ, Univ Med Ctr Mannheim, Dept Urol, Mannheim, Germany
[3] Virgen Rocio Univ Hosp, Urol & Nephrol Dept, Seville, Spain
[4] Sechenov Univ, Inst Urol & Reprod Hlth, Moscow, Russia
[5] Univ Modena & Reggio Emilia, Dept Urol, Modena, Italy
[6] Hosp Clin San Carlos, Dept Urol, Madrid, Spain
[7] Azienda Osped Univ Integrata Verona, Urol Unit, Verona, Italy
[8] IRCCS Azienda Osped Univ Bologna, Div Urol, Bologna, Italy
[9] Candiolo Canc Inst FPO IRCCS, Dept Surg, Turin, Italy
[10] Univ Southern Calif, Inst Urol, Los Angeles, CA USA
来源
关键词
Digital therapeutics; Patient perspective; Urology; App;
D O I
10.1016/j.euros.2023.07.003
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Digital therapeutics (DTx) are a new class of intervention involving evidence-based software applications and have been used in neurology and psychiatry. To assess the potential of DTx in urology, we conducted a survey to assess the current prevalence of the digital infrastructure required for DTx, areas of support expected by patients, and requirements for uptake. Between November 2022 and January 2023, we conducted an anonymized survey at two German academic centers among patients with urologic conditions. We found that among patients aged <65 yr versus >= 65 yr, digital devices including smartphones (93.6% vs 77.3%; p < 0.001), computers (80.4% vs 70.1%; p < 0.001), tablets (51.7% vs 38.1%; p < 0.001), and smartwatches (24.7% vs 7.7%; p < 0.001) are already widely used, especially in the younger age group. Apps (95.6% vs 74.4%; p < 0.001) and health apps (57.6% vs 30.4%; p < 0.001) are already frequently used, but certified DTx apps are not (7.3% vs 5.4%; p = 0.25). Patients favor solutions that provide access to validated information (49.6%), give medical advice based on data or symptoms captured by the app (43.0%), or replace a physiotherapist (41.7%). Patients feel that optimization of therapy (78.4%), significant positive health outcomes (76.9%), and better patient autonomy (73.4%) are important requirements for DTx in urology. Regulatory and reimbursement changes mean that DTx might play an increasing role in urology. Patient summary: Patients can use digital therapeutics (DTx), which are mainly smartphone apps, to improve their health status or treat medical conditions. We assessed the current and future use of DTx in urology. Patients are already widely using smartphones and frequently use uncertified health apps, but do not use DTx. Patients would like to use DTx to optimize therapy that provides a significant health improvement. (c) 2023 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:23 / 27
页数:5
相关论文
共 50 条